• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/5/25 4:35:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email
    Phibro Animal Health Corporation_November 4, 2025
    0001069899false00010698992025-11-042025-11-04

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ​

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): November 5, 2025 (November 4, 2025)

    Phibro Animal Health Corporation

    (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

    ​

    Delaware

        

    001-36410

        

    13-1840497

    (State or other jurisdiction of
    incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

    ​

    Glenpointe Centre East, 3rd Floor

    300 Frank W. Burr Boulevard, Suite 21

    Teaneck, New Jersey 07666-6712

    (Address of Principal Executive Offices, including Zip Code)

    ​

    (201) 329-7300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value per share

    ​

    PAHC

    ​

    NASDAQ Stock Market

    ​

    Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ITEM 2.02     RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

    On November 5, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

    On November 4, 2025, the Corporation held its annual meeting of stockholders (the “Meeting”). Present at the Meeting in person or by proxy were holders of 14,543,375 shares of Class A common stock of the Corporation and 20,166,034 shares of Class B common stock of the Corporation, which together represent 97.3% of the voting power of all shares of common stock of the Corporation as of September 12, 2025, the record date for the Meeting, and constituting a quorum for the transaction of business at the Meeting.

    The stockholders of the Corporation voted on the following items at the Meeting:

    1.To elect three Class III Directors to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified;
    2.To approve, on an advisory basis, the compensation of our named executive officers;
    3.To approve, on an advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers; and
    4.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2026.

    For more information about the foregoing proposals, see the Corporation’s 2025 Proxy Statement.

    Holders of the shares of Class A common stock are entitled to one vote per share and holders of the shares of Class B common stock are entitled to ten votes per share. Holders of the shares of Class A common stock and holders of the shares of Class B common stock voted together as a single class on all matters (including the election of directors) submitted to a vote of stockholders at the Meeting.

    The voting results for each of these proposals are detailed below.

    1.Election of Class III Directors

    ​

    ​

    ​

    ​

    Director Nominee

    Votes For

    Votes Withheld

    Broker Non-Votes

    Jack C. Bendheim

    207,953,285

    6,767,771

    1,482,659

    Alejandro Bernal

    208,667,720

    6,053,336

    1,482,659

    E. Thomas Corcoran

    206,223,871

    8,497,185

    1,482,659

    Based on the votes set forth above, each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified.

    ​

    2.Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers

    ​

    Votes For

    Votes Against

    Abstained

    Broker Non-Votes

    213,516,403

    1,184,154

    20,495

    1,482,663

    ​

    ​

    ​

    ​

    Based on the votes set forth above, the stockholders approved, on an advisory basis, the compensation of our named executive officers.

    ​

    3.Approval, on an Advisory Basis, of the Frequency of Future Stockholders Votes on the compensation of our named executive officers

    ​

    ​

    v

    ​

    Every 1 Year

    Every 2 Year

    Every 3 Year

    Abstained

    Broker Non-Votes

    12,065,906

    16,201

    202,618,936

    20,012

    1,482,660

    ​

    Based on the votes set forth above, the stockholders advised that they were in favor of three years as the frequency of holding a non-binding advisory vote on named executive officer compensation.

    ​

    4.Ratification of the Selection of PwC as Independent Registered Public Accounting Firm

    ​

    ​

    ​

    ​

    Votes For

    Votes Against

    Abstained

    214,368,092

    1,824,908

    10,713

    There were no broker non-votes on this proposal.

    Based on the votes set forth above, the stockholders ratified the selection of PwC as the Corporation’s independent registered public accounting firm for the fiscal year ending June 30, 2026.

    ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

    (d) Exhibits

    Exhibit
    Number

        

    Description

    99.1

     

    Press Release, dated November 5, 2025.

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    PHIBRO ANIMAL HEALTH CORPORATION

    Registrant

    ​

    ​

    Date: November 5, 2025

    ​

    ​

    ​

    ​

    By: 

    /s/ Judith Weinstein

    ​

    Name:

    Judith Weinstein

    ​

    Title:

    Senior Vice President, General Counsel and Corporate Secretary

    ​

    ​

    ​

    Get the next $PAHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAHC

    DatePrice TargetRatingAnalyst
    7/7/2025$35.00Neutral → Overweight
    Analyst
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    9/10/2024$22.00Neutral
    JP Morgan
    12/7/2023$9.00Underperform
    Exane BNP Paribas
    12/21/2022$18.00Buy
    ROTH Capital
    7/25/2022$22.00Equal Weight → Underweight
    Barclays
    1/10/2022$23.00Underweight → Equal-Weight
    Barclays
    11/18/2021$23.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PAHC
    SEC Filings

    View All

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    11/5/25 4:35:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Phibro Animal Health Corporation

    10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    11/5/25 4:14:14 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    11/4/25 4:15:56 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bendheim Jack sold $192,781 worth of shares (4,808 units at $40.10) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    12/10/25 4:15:20 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack converted options into 30,000 shares and sold $288,607 worth of shares (7,040 units at $41.00) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    12/4/25 6:34:41 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $296,376 worth of shares (7,040 units at $42.10) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    12/2/25 4:15:18 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phibro Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00

    7/7/25 8:10:48 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00

    6/16/25 8:16:19 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Phibro Animal Health with a new price target

    JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00

    9/10/24 7:55:45 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vis

    11/4/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs

    Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation. The launch of Restoris builds on our recently announced license agreement for a novel therapeutic product targeting periodontal health in companion animals through a different mechanism of action. Together, these products form the foundation of a

    10/30/25 1:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To a

    10/29/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Financials

    Live finance-specific insights

    View All

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vis

    11/4/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To a

    10/29/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    1/23/25 4:45:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    9/6/23 12:20:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and

    2/6/23 4:15:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care